

**Date:** May 31, 2021

To,  
BSE Limited,  
The Secretary,  
Listing Department,  
The BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001  
**Scrip ID/Code:** 540737

**Sub: Announcement under Regulation 30 of SEBI (LODR) Regulations, 2015, regarding Development of New Product.**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that the company has successfully developed a certain type of Cyclo-Propyl derivative, which is currently being imported by most of manufacturers in India for synthesis of the drugs like Naltrexone and Buprenorphine.

The said Cyclo-Propyl derivative is developed in the laboratory of the Company situated at Ankleshwar, Gujarat on May 31, 2021.

The said product will cater both Domestic and International Market and it's commercial production is expected to start by first week of June, 2021. As it a basic building block we expect that it will find usage over a wide range of applications and will attract huge volumes in upcoming years.

Kindly take the same on your records.

Thanking you,

Yours Faithfully

**For, Shree Ganesh Remedies Limited**

**Chandulal Manubhai Kothia**  
**Managing Director**  
**DIN: 00652806**

